← 返回

血液系统恶性肿瘤中的 CAR-T 细胞联合治疗

英文原题:CAR-T cell combination therapies in hematologic malignancies.

查看英文原题

CAR-T cell combination therapies in hematologic malignancies.

PubMed 2024/07/18(内容时间) Exp Hematol Oncol Q1 · IF 17.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CAR-T 是癌症治疗的重要突破,在血液恶性肿瘤中疗效显著,但单药治疗仍可能面临耐受和复发。研究者正探索与其他疗法联合以增强疗效。本文综述CAR-T 联合治疗血液肿瘤的研究进展,涵盖治疗基本原理及临床应用,并讨论其与化疗、免疫检查点抑制剂、靶向药物、放疗、造血干细胞移植及其他疗法的组合。不同机制的治疗联合可协同增强CAR-T 抗肿瘤作用,从而改善患者应答和生存。

展开英文摘要原文

Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved remarkable success against hematologic malignancies.

However, CAR-T monotherapy faces challenges in certain cases, including treatment tolerance and relapse rates. To overcome these challenges, researchers are investigating combining CAR-T cells with other treatments to enhance therapeutic efficacy.

Therefore, this review aims to investigate the progress of research in combining CAR-T cells for hematologic malignancies. It covers the basic principles and clinical applications of CAR-T cell therapy, detailing combinations with chemotherapy, immune checkpoint inhibitors, targeted drugs, radiotherapy, hematopoietic stem cell transplantation, and other treatments. These combinations synergistically enhance the antitumor effects of CAR-T cells and comprehensively target tumors through different mechanisms, improving patient response and survival rates.

论文信息

作者
Zhou D、Zhu X、Xiao Y
第一作者单位
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.China
通讯作者单位
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. yixiao@tjh.tjmu.edu.cn.China
文献类型
综述
期刊
Experimental hematology & oncology2024 Jul 18
原文标识
PubMed 39026380 · DOI 10.1186/s40164-024-00536-0